What this means
This is a review that pulls together earlier research on aging immune cells and cancer treatment. It says chronological age alone does not reliably predict how people respond to immunotherapy.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- A review of earlier studies, not a new test in people
- Kind of research
- A summary of earlier studies
The science
- Original title
- Tumor-associated immunosenescence: Mechanisms, biomarkers and age-adaptive immunotherapy.
- Authors
- Wu H, Yang Z, Zhang H et al.
- Journal
- Critical reviews in oncology/hematology
- Published
- Oct 12, 2026
- Study type
- Review
- PMID
- 42863771 ↗
Abstract
Immunosenescence alters immune-cell composition, signaling, metabolism, and regenerative capacity, but chronological age alone does not reliably predict response to cancer immunotherapy. In older adults, thymic involution, hematopoietic remodeling, inflammaging, and the accumulation of dysfunctional lymphoid and myeloid populations interact with tumor-derived suppressive signals. We organize these processes within an Immunosenescence-Immunotherapy Interference Axis linking systemic immune aging, local tumor remodeling, and treatment-specific vulnerabilities. Evidence is reviewed for senescence-like and exhausted CD8 + T cells, NK-cell dysfunction, age-associated macrophage states, loss of T-cell receptor diversity, and their relationship to immune checkpoint blockade. We then assess blood, tissue, and single-cell biomarkers that may distinguish biological immune age from chronological age, with particular attention to the limitations of single-marker classification. Finally, we critically evaluate senolytics, cytokine support, co-stimulatory approaches, and metabolic modulation as potential adjuncts to immunotherapy. The available evidence supports biomarker-informed, age-adaptive trial design, but prospective validation is required before immune-rejuvenation strategies can be recommended in routine oncology.
Wu H, Yang Z, Zhang H et al. Tumor-associated immunosenescence: Mechanisms, biomarkers and age-adaptive immunotherapy. Critical reviews in oncology/hematology. 2026. doi:10.1016/j.critrevonc.2026.105647. PMID: 42863771. https://pubmed.ncbi.nlm.nih.gov/42863771/
Related research
A drug pair tested in people with fatty liver disease and scarring
In this small trial, more people on dasatinib plus quercetin had liver scarring improve than those on placebo. The trial was small, and it does not show the drugs are safe or work for everyone.
Old, stuck cells may sometimes help cancer resist treatment
This review looks at how cells that stop dividing after cancer treatment might sometimes help tumors survive. The authors say these cells play a role only in some cases, not in every case.
How cancer treatment may age the heart and blood vessels in breast cancer patients
This review looks at how cancer treatments can leave some cells stuck in an aging state that may harm the heart. It does not prove this process causes heart damage, since other factors can also play a part.
A tea plant root extract killed aging skin cells in a lab dish
Researchers tested a tea root extract on human skin cells that had been made old in a dish. The extract killed more of the old cells than normal ones, and it also cut some inflammation signals. This does not show the extract works in people, because the tests were done in cells and skin samples.
Cell aging after cancer treatment may help or hurt tumour growth
This paper is a review of earlier research on aged cells and cancer. It says these cells may either slow or speed up tumour growth.
A review of how damaged nerves in the body repair their protective coating
This review gathers what is known about how nerve cells rebuild their coating after injury. It does not test a new treatment, and it suggests future treatments may need to be combined.
See all research on Senolytics →